Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals’ stock rose to a record high of $84.8, lifting its market capitalization to about $9 billion. The company reported strong revenue growth with net product revenues of $24.0 million in Q2 2026 and total revenue of $25.1 million. The planned roughly $10 billion acquisition by Vertex has advanced following regulatory approvals, but analysts reacted with downgrades. Data indicate the stock may be temporarily above its fair value and overbought. » Más en de.investing.com

The planned takeover of Crinetics by Vertex has passed important antitrust waiting periods and received approvals in Austria, Germany and Australia. The transaction envisages a cash price of $85 per share (around $10 billion) and remains subject, among other things, to approval by Crinetics shareholders on August 28, 2026; closing is expected in early September or in the third quarter of 2026. Crinetics shares are trading near their 52-week high, and the company reported strong revenue growth for Palsonify in the second quarter of 2026. » Más en de.investing.com

Crinetics Pharmaceuticals shares rose to a record high of $84.35 and are trading near their 52-week high; market capitalization is about $8.94 billion. Vertex announced a takeover of Crinetics for $85 per share (about $10 billion), with completion expected in Q3 2026. Crinetics reported strong revenue growth driven by Palsonify (Q2 revenue $24.0 million; total revenue $25.1 million) and has posted double-digit gains year-to-date, while some analysts have cut ratings from buy to neutral/hold and InvestingPro flags overbought RSI signals and possible overvaluation. » Más en de.investing.com